CLINICAL TRIALS PROFILE FOR DOPAMINE HYDROCHLORIDE IN DEXTROSE 5% IN PLASTIC CONTAINER

505(b)(2) Clinical Trials for DOPAMINE HYDROCHLORIDE IN DEXTROSE 5% IN PLASTIC CONTAINER

This table shows clinical trials for potential 505(b)(2) applications. See the next table for all clinical trials

Trial Type	Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
OTC	NCT00405912 ↗	St. John's Wort for Tobacco Cessation	Completed	National Cancer Institute (NCI)	Phase 2	2005-09-01	After a steady decline for the last 50 years, the prevalence of tobacco use in the United States has reached a plateau of approximately 23%. Currently available treatments among adults are expensive and not efficacious for all tobacco users. New pharmacologic agents need to be developed and tested to achieve the Healthy People 2010 goal of less than a 12% adult tobacco use prevalence. Bupropion, an FDA approved agent for tobacco cessation, acts by inhibiting central synaptosomal reuptake of dopamine and norepinephrine. A widely used herbal antidepressant, St. John's Wort (SJW), shares a similar mechanism of action and is effective for treating mild to moderate depression. SJW is well tolerated, available over the counter, and is significantly less expensive than the established treatments for tobacco dependence. To date, no prospective clinical trial evaluating the efficacy of SJW for the treatment of tobacco use has been published. We propose to evaluate the efficacy of SJW for increasing tobacco abstinence and decreasing nicotine withdrawal symptoms in a randomized, double-blind, placebo-controlled, three-arm, parallel group, dose-ranging clinical trial. Participants (N=120) will be randomly assigned to one of the three groups and will receive a twelve-week course of SJW 900 mg per day, 1800 mg per day, or a matching placebo. This study is anticipated to provide the data needed to develop a larger randomized controlled clinical trial submitted through the R01 funding mechanism.
OTC	NCT00405912 ↗	St. John's Wort for Tobacco Cessation	Completed	Mayo Clinic	Phase 2	2005-09-01	After a steady decline for the last 50 years, the prevalence of tobacco use in the United States has reached a plateau of approximately 23%. Currently available treatments among adults are expensive and not efficacious for all tobacco users. New pharmacologic agents need to be developed and tested to achieve the Healthy People 2010 goal of less than a 12% adult tobacco use prevalence. Bupropion, an FDA approved agent for tobacco cessation, acts by inhibiting central synaptosomal reuptake of dopamine and norepinephrine. A widely used herbal antidepressant, St. John's Wort (SJW), shares a similar mechanism of action and is effective for treating mild to moderate depression. SJW is well tolerated, available over the counter, and is significantly less expensive than the established treatments for tobacco dependence. To date, no prospective clinical trial evaluating the efficacy of SJW for the treatment of tobacco use has been published. We propose to evaluate the efficacy of SJW for increasing tobacco abstinence and decreasing nicotine withdrawal symptoms in a randomized, double-blind, placebo-controlled, three-arm, parallel group, dose-ranging clinical trial. Participants (N=120) will be randomly assigned to one of the three groups and will receive a twelve-week course of SJW 900 mg per day, 1800 mg per day, or a matching placebo. This study is anticipated to provide the data needed to develop a larger randomized controlled clinical trial submitted through the R01 funding mechanism.
New Formulation	NCT00640159 ↗	Tolerability and Efficacy of Switch From Oral Selegiline to Orally Disintegrating Selegiline (Zelapar) in Patients With Parkinson's Disease	Completed	Baylor College of Medicine	Phase 4	2007-01-01	Parkinson's disease (PD) is a progressive neurodegenerative disease. Symptomatic therapy is primarily aimed at restoring dopamine function in the brain. Oral selegiline in conjunction with L-dopa has been a mainstay of therapy for PD patients experiencing motor fluctuations for many years. The mechanisms accounting for selegiline's beneficial adjunctive action in the treatment of PD are not fully understood. Inhibition of monoamine oxidase (MAO) type B (MAO-B) activity is generally considered to be of primary importance. Oral selegiline has low bio-availability and is typically dosed BID, for a total of 5-10 mg daily. Recently, the FDA approved a new orally disintegration tablet (ODT) formulation of selegiline, called ZelaparTM. This new formulation utilizes Zydis technology to dissolve in the mouth, with absorption through the oral mucosa, thereby largely bypassing the gut and avoiding first pass hepatic metabolism. This allows more active drug to be delivered at a lower dose. Consequently, Zelapar is dosed once-daily, up to 2.5 mg per day. There are no empirical data indicating whether the use of the new approved formulation of selegiline ODT (Zelapar) is superior or preferred by patients compared to traditional oral selegiline. It is believed that clinical efficacy will be preserved or enhanced, by delivering more active drug, with improved patient preference for the ODT formulation due to the once-daily dosing . The effectiveness of orally disintegrating selegiline as an adjunct to carbidopa/levodopa in the treatment of PD was established in a multicenter randomized placebo-controlled trial (n=140; 94 received orally disintegrating selegiline, 46 received placebo) of three months' duration. Patients randomized to orally disintegrating selegiline received a daily dose of 1.25 mg for the first 6 weeks and a daily dose of 2.5 mg for the last 6 weeks. Patients were all treated with levodopa and could additionally have been on dopamine agonists, anticholinergics, amantadine, or any combination of these during the trial. At 12 weeks, orally disintegrating selegiline-treated patients had an average of 2.2 hours per day less "OFF" time compared to baseline. Placebo treated patients had 0.6 hours per day less "OFF" time compared to baseline. These differences were significant (p < 0.001). Adverse events were very similar between drug and placebo.
OTC	NCT00722124 ↗	S-Adenosyl-L-Methionine (SAMe) for Smoking Abstinence	Completed	Pharmavite	Phase 2/Phase 3	2008-09-01	Cigarette smoking is of great public health importance and is the single most important preventable cause of morbidity, mortality and excess health care costs in the United States. After a steady decline for the last 50 years, the prevalence of tobacco use in the United States has reached a plateau of approximately 21%. Currently available treatments among adults are not efficacious for all tobacco users. New pharmacologic agents thus need to be continually developed and tested. The release of dopamine in the nucleus accumbens is one of the key components of the pleasurable and rewarding effects of nicotine. Drugs that increase monoamine neurotransmitter availability (particularly dopamine and norepinephrine) are likely to increase the reward function and thus ameliorate withdrawal symptoms. S-Adenosyl-L-Methionine (SAMe), the primary methyl donor for the central nervous system (CNS), donates methyl groups towards presynaptic synthesis of CNS monoamine neurotransmitters. By facilitating the synthesis of dopamine and norepinephrine in the brain, SAMe is likely to ameliorate the symptoms of nicotine withdrawal, thus improving tobacco abstinence rates in smokers who are trying to stop smoking. SAMe is well tolerated and is available over-the-counter. To date, no prospective clinical trial evaluating the efficacy of SAMe for the treatment of tobacco dependence has been published. We propose to evaluate the efficacy of SAMe for increasing smoking abstinence and decreasing nicotine withdrawal symptoms in a randomized, blinded, placebo-controlled, three-arm, parallel-group, dose-ranging phase II clinical trial. Participants (N=120) will be randomly assigned to one of the three groups, and will receive an 8-week course of SAMe 800-mg per day, 1600-mg per day, or a matching placebo. This study is anticipated to provide the data needed to develop a larger randomized controlled clinical trial submitted through the R01 funding mechanism, if the results appear promising.
OTC	NCT00722124 ↗	S-Adenosyl-L-Methionine (SAMe) for Smoking Abstinence	Completed	Pharmavite LLC	Phase 2/Phase 3	2008-09-01	Cigarette smoking is of great public health importance and is the single most important preventable cause of morbidity, mortality and excess health care costs in the United States. After a steady decline for the last 50 years, the prevalence of tobacco use in the United States has reached a plateau of approximately 21%. Currently available treatments among adults are not efficacious for all tobacco users. New pharmacologic agents thus need to be continually developed and tested. The release of dopamine in the nucleus accumbens is one of the key components of the pleasurable and rewarding effects of nicotine. Drugs that increase monoamine neurotransmitter availability (particularly dopamine and norepinephrine) are likely to increase the reward function and thus ameliorate withdrawal symptoms. S-Adenosyl-L-Methionine (SAMe), the primary methyl donor for the central nervous system (CNS), donates methyl groups towards presynaptic synthesis of CNS monoamine neurotransmitters. By facilitating the synthesis of dopamine and norepinephrine in the brain, SAMe is likely to ameliorate the symptoms of nicotine withdrawal, thus improving tobacco abstinence rates in smokers who are trying to stop smoking. SAMe is well tolerated and is available over-the-counter. To date, no prospective clinical trial evaluating the efficacy of SAMe for the treatment of tobacco dependence has been published. We propose to evaluate the efficacy of SAMe for increasing smoking abstinence and decreasing nicotine withdrawal symptoms in a randomized, blinded, placebo-controlled, three-arm, parallel-group, dose-ranging phase II clinical trial. Participants (N=120) will be randomly assigned to one of the three groups, and will receive an 8-week course of SAMe 800-mg per day, 1600-mg per day, or a matching placebo. This study is anticipated to provide the data needed to develop a larger randomized controlled clinical trial submitted through the R01 funding mechanism, if the results appear promising.
OTC	NCT00722124 ↗	S-Adenosyl-L-Methionine (SAMe) for Smoking Abstinence	Completed	Mayo Clinic	Phase 2/Phase 3	2008-09-01	Cigarette smoking is of great public health importance and is the single most important preventable cause of morbidity, mortality and excess health care costs in the United States. After a steady decline for the last 50 years, the prevalence of tobacco use in the United States has reached a plateau of approximately 21%. Currently available treatments among adults are not efficacious for all tobacco users. New pharmacologic agents thus need to be continually developed and tested. The release of dopamine in the nucleus accumbens is one of the key components of the pleasurable and rewarding effects of nicotine. Drugs that increase monoamine neurotransmitter availability (particularly dopamine and norepinephrine) are likely to increase the reward function and thus ameliorate withdrawal symptoms. S-Adenosyl-L-Methionine (SAMe), the primary methyl donor for the central nervous system (CNS), donates methyl groups towards presynaptic synthesis of CNS monoamine neurotransmitters. By facilitating the synthesis of dopamine and norepinephrine in the brain, SAMe is likely to ameliorate the symptoms of nicotine withdrawal, thus improving tobacco abstinence rates in smokers who are trying to stop smoking. SAMe is well tolerated and is available over-the-counter. To date, no prospective clinical trial evaluating the efficacy of SAMe for the treatment of tobacco dependence has been published. We propose to evaluate the efficacy of SAMe for increasing smoking abstinence and decreasing nicotine withdrawal symptoms in a randomized, blinded, placebo-controlled, three-arm, parallel-group, dose-ranging phase II clinical trial. Participants (N=120) will be randomly assigned to one of the three groups, and will receive an 8-week course of SAMe 800-mg per day, 1600-mg per day, or a matching placebo. This study is anticipated to provide the data needed to develop a larger randomized controlled clinical trial submitted through the R01 funding mechanism, if the results appear promising.

All Clinical Trials for DOPAMINE HYDROCHLORIDE IN DEXTROSE 5% IN PLASTIC CONTAINER

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT00000276 ↗	Dopamine Reuptake Inhibitors of Cocaine Abuse - 1	Terminated	National Institute on Drug Abuse (NIDA)	Phase 1	1994-09-01	The purpose of this study is to evaluate dopamine reuptake inhibitors for cocaine abuse.
NCT00000276 ↗	Dopamine Reuptake Inhibitors of Cocaine Abuse - 1	Terminated	VA Connecticut Healthcare System	Phase 1	1994-09-01	The purpose of this study is to evaluate dopamine reuptake inhibitors for cocaine abuse.
NCT00000276 ↗	Dopamine Reuptake Inhibitors of Cocaine Abuse - 1	Terminated	Yale University	Phase 1	1994-09-01	The purpose of this study is to evaluate dopamine reuptake inhibitors for cocaine abuse.
NCT00000309 ↗	Serotonin/Dopamine Antagonism of Cocaine Effect: 1 - 1	Terminated	National Institute on Drug Abuse (NIDA)	Phase 2	1994-08-01	The purpose of this study is to evaluate use of risperidone with cocaine abusers. Study measures incorporate an appropriate integration of behavioral and neurobiological indices.
NCT00000309 ↗	Serotonin/Dopamine Antagonism of Cocaine Effect: 1 - 1	Terminated	VA Boston Healthcare System	Phase 2	1994-08-01	The purpose of this study is to evaluate use of risperidone with cocaine abusers. Study measures incorporate an appropriate integration of behavioral and neurobiological indices.
NCT00000309 ↗	Serotonin/Dopamine Antagonism of Cocaine Effect: 1 - 1	Terminated	Butler Hospital	Phase 2	1994-08-01	The purpose of this study is to evaluate use of risperidone with cocaine abusers. Study measures incorporate an appropriate integration of behavioral and neurobiological indices.

Clinical Trial Conditions for DOPAMINE HYDROCHLORIDE IN DEXTROSE 5% IN PLASTIC CONTAINER

Condition Name

Condition Name for DOPAMINE HYDROCHLORIDE IN DEXTROSE 5% IN PLASTIC CONTAINER
Intervention	Trials
Schizophrenia	101
Parkinson Disease	86
Parkinson's Disease	74
Healthy	37

Condition MeSH

Condition MeSH for DOPAMINE HYDROCHLORIDE IN DEXTROSE 5% IN PLASTIC CONTAINER
Intervention	Trials
Parkinson Disease	190
Schizophrenia	111
Disease	76
Depression	70

Clinical Trial Locations for DOPAMINE HYDROCHLORIDE IN DEXTROSE 5% IN PLASTIC CONTAINER

Trials by Country

Trials by Country for DOPAMINE HYDROCHLORIDE IN DEXTROSE 5% IN PLASTIC CONTAINER
Location	Trials
Canada	83
Germany	67
France	58
United Kingdom	47
China	42

Trials by US State

Trials by US State for DOPAMINE HYDROCHLORIDE IN DEXTROSE 5% IN PLASTIC CONTAINER
Location	Trials
New York	87
California	85
Maryland	72
Massachusetts	58
Connecticut	54

Clinical Trial Progress for DOPAMINE HYDROCHLORIDE IN DEXTROSE 5% IN PLASTIC CONTAINER

Clinical Trial Phase

Clinical Trial Phase for DOPAMINE HYDROCHLORIDE IN DEXTROSE 5% IN PLASTIC CONTAINER
Clinical Trial Phase	Trials
PHASE4	13
PHASE3	6
PHASE2	29

Clinical Trial Status

Clinical Trial Status for DOPAMINE HYDROCHLORIDE IN DEXTROSE 5% IN PLASTIC CONTAINER
Clinical Trial Phase	Trials
Completed	585
RECRUITING	173
Unknown status	95

Clinical Trial Sponsors for DOPAMINE HYDROCHLORIDE IN DEXTROSE 5% IN PLASTIC CONTAINER

Sponsor Name

Sponsor Name for DOPAMINE HYDROCHLORIDE IN DEXTROSE 5% IN PLASTIC CONTAINER
Sponsor	Trials
National Institute on Drug Abuse (NIDA)	64
National Institute of Mental Health (NIMH)	47
Yale University	30

Sponsor Type

Sponsor Type for DOPAMINE HYDROCHLORIDE IN DEXTROSE 5% IN PLASTIC CONTAINER
Sponsor	Trials
Other	1446
Industry	255
NIH	200

Last updated: May 26, 2026

Dopamine Hydrochloride in Dextrose 5% in Plastic Container (D5W) Clinical Trials Update, Market Analysis, and Revenue Projections

Executive summary: Dopamine hydrochloride in Dextrose 5% in plastic container is a niche, hospital-administered injectable used in acute settings (e.g., shock states requiring inotrope/vasopressor support). Market size and near-term growth are driven by hospital utilization, formulary access, and supply continuity rather than repeat outpatient use. Commercial upside is constrained by commoditization risk, generic/authorized generic availability, and substitution across dopamine injectable presentations. Clinical development for dopamine as an active is largely incremental (formulation, container closure, stability, and manufacturing), with limited evidence of broad new phase programs. A defensible projection therefore depends on (i) current FDA-approved product and label scope, (ii) exclusivity and patent estate status for the specific presentation/container, and (iii) institutional purchasing and tender cycles.

---

Is there an active clinical trial pipeline for Dopamine HCl in Dextrose 5% (plastic container)?

Featured-snippet answer: Publicly observable “dopamine hydrochloride + D5W + plastic container” trials are typically scarce. Most contemporary dopamine clinical activity is either guideline-driven comparative effectiveness (across pressors/inotropes) or studies using existing approved dopamine products without packaging-specific investigation.

What trial types are most likely for this drug category

• Formulation and stability studies tied to specific container systems (plastic container, line compatibility, sorption).
• Bioequivalence is less central for dopamine injectables; trials often target manufacturing comparability or stability rather than pharmacokinetic bridging.
• Clinical evidence tends to be class-level (dopamine versus other vasopressors/inotropes) rather than product-presentation specific.

Which endpoints define “new value” in this space

• Safety endpoints: arrhythmias, tachycardia, ischemia events.
• Hemodynamics: MAP change, vasopressor-free time.
• Practical endpoints: infusion compatibility, line occlusion incidence, particulate matter controls, stability under simulated use.

How to interpret “pipeline” absence

• Lack of large-scale, actively recruiting product trials usually points to a settled active ingredient and competitive substitution across dopamine injectable SKUs.
• Commercial and regulatory risk shifts toward supply, labeling, and container-specific quality systems rather than differentiated clinical efficacy.

---

What does the latest clinical evidence say for dopamine in shock, and does it support this presentation?

Featured-snippet answer: Clinical use of dopamine as a pressor/inotrope is guideline-dependent and often deprioritized relative to alternatives in many protocols, but it remains relevant in specific settings and workflows.

Where dopamine remains used

• Acute care settings where inotropy and vasopressor support are needed.
• Settings where local formulary and procurement have entrenched dopamine injectable utilization.

What tends to reduce growth

• Preference shifts toward norepinephrine or other agents for shock management in many protocols.
• Risk management focus (tachyarrhythmias) can drive formulary tightening.

Why packaging can still matter

Even when clinical positioning is stable, presentation affects:

• Stocking decisions (plastic container vs glass).
• Compatibility with common ICU infusion sets.
• Shelf-life and storage logistics at health systems.

---

What patents and exclusivity protect Dopamine HCl in D5W plastic container, and how does that affect competition?

Featured-snippet answer: For generic-dominated injectable categories, protection often narrows to formulation details (container/closure, concentration, manufacturing process) rather than broad active-ingredient exclusivity.

What typically protects this exact presentation

• Specific composition claims around dopamine hydrochloride in D5W at defined strengths.
• Container closure system claims tied to stability or low adsorption.
• Manufacturing process claims (mixing, filtration, sterilization, filling parameters).
• Packaging method claims that bind to “plastic container” and its material system.

How to map patent estate to competitive risk

• If only legacy patents exist: multiple authorized generics and generics can supply.
• If formulation or method claims are still in force: generic entry can be delayed or designed around claim scope (different container material, different fill composition, different strength, or process changes).

---

What is the Orange Book status of dopamine hydrochloride in D5W in plastic container?

Featured-snippet answer: Orange Book coverage exists at the NDA/ANDA product level. For this specific container presentation, the practical question is whether multiple ANDAs are already listed with approvals and whether any are tied to unexpired exclusivity or active patents.

What to look for on the Orange Book listing (for this SKU)

• NDA holder(s) and dosage form match (injectable, D5W solution).
• Patent numbers and their expiration dates for the exact listed formulation/container.
• “Exclusivity” type if applicable (often not present for older injectables beyond basic exclusivity).

Why Orange Book diligence matters for market projections

• Patent and exclusivity status determines whether procurement stays locked to the originator for a remaining period or shifts to low-cost generics and tender-led pricing.

---

Which companies supply Dopamine HCl in D5W plastic container in the US, and how does that shape pricing?

Featured-snippet answer: Supply is typically fragmented across generic manufacturers and authorized generics for older injectable actives. Pricing is usually driven by acquisition cost, tender outcomes, and contract manufacturing capacity.

Competition patterns

• Multiple ANDA suppliers reduce pricing power.
• Health systems standardize across fewer SKUs for formulary simplification, which can create short-term volume concentration with one or two preferred suppliers.
• Supply disruptions can temporarily reprice demand toward available SKUs.

Market behavior to model

• Contract pricing floors with periodic rebids.
• Shortage-related price spikes are episodic, not structural, unless supply consolidation occurs.

---

When do generics or authorized generics face launch risk for this presentation, and how soon could they take share?

Featured-snippet answer: The main timing lever is whether any patent-listed protection blocks generic supply for the exact product presentation. For older injectables, launch risk is more “already occurred” than “about to occur,” meaning share shifts depend on tenders, not on new entry.

Paragraph IV likelihood

• Older, widely generic-dosed products often see fewer active Paragraph IV events for the same SKU because most lower-cost options already exist.
• New challenges are more likely to target formulation- or process-specific patents that have not expired.

Settlement-driven entry schedules

• If patent challenges occur, generic entry timing is often determined by settlement dates or dismissal dates rather than statutory expiration.

---

What patent litigation affects this drug category, and how would it change supply?

Featured-snippet answer: Litigation for dopamine injectables is usually tied to ANDA approvals and formulation/patent listings. Where present, settlements can delay launch or impose market allocation.

Litigation levers

• Injunction risk for specific strengths and presentations.
• Carve-outs in settlement agreements (some strengths may launch sooner than others).
• “Design-around” substitutions (different container type, different fill volume, or alternative D5W concentration).

Supply impact mechanism

Even when new entrants win or settle, real-world supply depends on manufacturing readiness, fill-finish capacity, and logistics.

---

How strong is the patent estate for Dopamine HCl injectables, and what is the generic entry barrier?

Featured-snippet answer: For commodity injectables, patent estate strength is usually moderate to low unless the specific presentation has late-expiring formulation/process claims.

Barrier components

• Remaining unexpired patents for the exact formulation and container.
• Ability to use a non-infringing manufacturing route.
• Regulatory pathway compliance (ANDA comparability, stability data for the specific container system).

Commercial barrier

Even with patent clearance, adoption depends on:

• Hospital formulary processes.
• Value analysis committee approval.
• Compatibility with infusion workflows.

---

What is the current market size, growth rate, and unit demand profile for dopamine injectables (proxy for this SKU)?

Featured-snippet answer: Market size for dopamine injectables is primarily a function of acute-care volume and formulary penetration. For a single presentation like “D5W in plastic container,” the addressable market is the fraction of overall dopamine injectable utilization that prefers that specific container for logistics and compatibility.

How to structure market modeling

• Demand drivers: ICU admissions and shock/instability protocols; emergency department utilization.
• Utilization drivers: hospital standardization and substitution rates between dopamine and other inotropes/pressors.
• Supply constraints: shortages, fill-finish capacity, and distribution constraints.

Segmentation approach used for projections

• Geography: US dominates for major injectable footprints; EU/UK differ by tender regimes.
• Care setting: ICU, ED, OR recovery.
• Strength/volume: utilization varies by concentration and infusion protocols.
• Container preference: plastic containers often align with workflow and storage requirements.

(This section is deliberately presentation-agnostic because the specific SKU’s transactional market data is not provided in the prompt.)

---

How should revenue projections be built for Dopamine HCl in D5W plastic container?

Featured-snippet answer: Build projections off (i) base institutional demand, (ii) penetration of the specific container/presentation, (iii) price net of tender concessions, and (iv) supply availability and substitution dynamics.

Projection model skeleton

1. Base units (annual doses) = total ICU/acute shock utilizations that include dopamine × dopamine share.
2. SKU share = plastic container share within dopamine injectable usage.
3. Net price = contracted price weighted by account types minus rebates and distribution economics.
4. Adoption changes:
   • Switch driven by tender outcomes (fast)
   • Switch driven by supply outages (episodic)
   • Protocol-driven substitution away from dopamine (gradual)

Scenario set

• Base case: stable utilization with modest price erosion typical for generics.
• Bear case: continued protocol substitution reduces dopamine share; competitive pressure increases.
• Bull case: improved availability + formulary standardization on plastic container drives SKU share.

---

Which regulatory milestones matter for this specific injectable and presentation?

Featured-snippet answer: For this type of drug, the regulatory schedule is typically dominated by ANDA reporting obligations, cGMP inspections, and any annual product quality updates. Major new regulatory milestones are not common unless sponsors pursue line extensions, container changes, or manufacturing transfers.

What to monitor

• ANDA approval changes linked to manufacturing sites (annual reports, prior approval supplements).
• Labeling updates reflecting safety communications or compendial changes.
• Stability and container closure performance supporting continued shelf life.

---

What is the competitive landscape versus alternative vasopressors/inotropes used in shock?

Featured-snippet answer: Dopamine’s competitive pressure comes from alternatives that many protocols favor for shock management, including norepinephrine-based approaches.

Why alternatives matter for dopamine’s volume

• Protocols can downshift dopamine usage even if dopamine remains available.
• Formulary decisions often reflect safety profiles and clinician practice patterns.

Net effect on this SKU

• Even if dopamine presentation quality is adequate, volume can erode if dopamine is deprioritized clinically.
• The remaining value for the SKU is reliability and cost-effective supply in institutions that still use dopamine.

---

What generic entry risks exist for Dopamine HCl in D5W plastic container?

Featured-snippet answer: Generic entry risks are mostly already realized for older dopamine injectables. The remaining risks are tied to protection of the specific presentation and manufacturing process rather than a late-stage, first-in-class generic wave.

Where new entrants can still face friction

• Container closure system constraints that require validation.
• Process parameter differences that can create comparability issues.
• Patent barriers for packaging/formulation claims tied to stability and adsorption characteristics.

---

Key Takeaways

• Clinical trials specifically tied to “dopamine hydrochloride in D5W in plastic container” are usually limited; value is typically driven by formulation, stability, and supply continuity rather than new efficacy.
• Market growth is constrained by dopamine’s commoditized injectable status and protocol-driven competition from alternative vasopressors/inotropes.
• Revenue projections should be modeled around institutional acute-care utilization, the fraction using dopamine, and the share that selects the plastic-container presentation, then stress-tested for price erosion and protocol substitution.
• Competitive dynamics are shaped by tender cycles and supply availability more than by new clinical evidence.

---

FAQs

1. How do container and closure systems affect stability and adoption for dopamine hydrochloride D5W injectables?
2. Does Orange Book patent protection for dopamine injectables typically cover the container presentation or the active ingredient only?
3. Are Paragraph IV challenges common for older dopamine hydrochloride injectable presentations?
4. What factors determine whether a hospital formulary shifts from dopamine to alternative vasopressors in shock?
5. How should a manufacturer price dopamine hydrochloride D5W plastic container contracts against authorized generics?

---

References

1. FDA. Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations. US Food and Drug Administration. https://www.accessdata.fda.gov/scripts/cder/daf/ (accessed 2026-05-26).